Nexus Pharmaceuticals
  • Home
  • Our Company
    • About Us
    • Focus and Responsibility
    • Commitment to Quality
    • Team and Culture
  • Diverse Supplier
    • Nexus Procurement Services
  • Products
  • Careers
  • News
    • Latest News
    • State-of-the- Art Manufacturing Facility
  • Contact Us
Select Page
Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin

Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin

by Patrick Weeks | Jul 11, 2019 | News

● The multi-stage, multi-year project is expected to be completed in ten years, with an estimated investment of $250m. ● The only project of its kind in sterile generic injectables in the last 30 years. ● The facility will be located in Pleasant Prairie, Wisconsin,...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

by Patrick Weeks | Feb 21, 2019 | News, Product Approvals

Lincolnshire, Ill., February 21, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. “The launch further expands our generic injectable portfolio...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Announces FDA Approval of Dicyclomine HCl Injection, USP

by Patrick Weeks | Feb 14, 2019 | News, Product Approvals

Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP,...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Announces FDA Approval of Busulfan Injection

by Patrick Weeks | Jan 16, 2019 | News, Product Approvals

Lincolnshire, Ill., January 16, 2019 — Nexus Pharmaceuticals Inc. announced today the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL). “The FDA approval of...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Receives FDA Approval for Arsenic Trioxide Injection in 10mg per 10mL Vial

by Patrick Weeks | Nov 15, 2018 | News, Product Approvals

Vernon Hills, IL., Nov. 15th, 2018 – Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals’ Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection. The product...
« Older Entries
© 2022 Nexus Pharmaceuticals, Inc.
  • Du kan l sa mer om tj nsten p v r hemsida.
  • Farmaci per l'Impotenza
  • In some embodiments of formula (I), R 3 is selected from.
  • No pathological signs were noted during necropsy.
  • Og oftest er disse m nd helt ude af balance her.
  • Quindi, tenete gli occhi aperti!
  • Un traitement quotidien contre l'impuissance
  • What is Tocilizumab (Actemra®)?